`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`
`MYLAN TECHNOLOGIES, INC.
`Petitioner
`v.
`
`NOVEN PHARMACEUTICALS, INC.
`Patent Owner.
`
`_______________
`
`Case No. IPR2018-00174
`U.S. Patent No. 9,730,900
`____________________________________________________________
`
`
`NOVEN PHARMACEUTICALS, INC.’S
`FIRST UPDATED MANDATORY NOTICE
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`4850-2264-5352.1
`
`
`
`
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), Petitioner Noven Pharmaceuticals
`
`(“Noven”) hereby files its first Updated Mandatory Notice:
`
`I.
`
`Related Matters Pursuant to 37 C.F.R. § 42.8 (b)(2):
`
`Noven hereby updates the initial Mandatory Notices filed December 21,
`
`2017, to identify the following judicial or administrative matters that may affect, or
`
`be affected by, a decision in the instant proceeding:
`
`U.S. Patent No. 9,730,900 (“the ’900 patent”), which is the subject of the
`
`present IPR petition, and U.S. Patent No. 9,724,310 (“the ’310 patent”), which is
`
`the subject of petition IPR2018-00173, are now being asserted in the following
`
`patent infringement lawsuits currently pending in the United States District Court
`
`for the District of Delaware: (1) Noven Pharmaceuticals, Inc. v. Amneal
`
`Pharmaceuticals LLC, C.A. No. 1-18-cv-00699-LPS (D. Del.); and (2) Noven
`
`Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., C.A. No. 1-18-cv-00758-
`
`LPS (D. Del.).
`
`U.S. Patent No. 8,231,906 (“the ’906 patent”), which both the ’900 patent
`
`and the ’310 patent claim priority to, is also being asserted in Noven
`
`Pharmaceuticals, Inc. v. Amneal Pharmaceuticals LLC, C.A. No. 1-18-cv-00699-
`
`LPS (D. Del.).
`
`U.S. Patent No. 9,833,419 (“the ’419 patent”), which claims priority to the
`
`4850-2264-5352.1
`
`1
`
`
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`’310 patent, the ’900 patent, and the ’906 patent, is now the subject of a petition for
`
`Inter Partes Review, IPR2018-01119, filed on May 18, 2018. The ’419 patent is
`
`being asserted in the following patent infringement lawsuits currently pending in
`
`the United States District Court for the District of Delaware: (1) Noven
`
`Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC et al., C.A. No. 1-17-cv-01429-
`
`LPS (D. Del.); (2) Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc. et al.,
`
`C.A. No. 1-17-cv-01777-LPS (D. Del.); (3) Noven Pharmaceuticals, Inc. v.
`
`Amneal Pharmaceuticals LLC, C.A. No. 1-18-cv-00699-LPS (D. Del.); and
`
`(4) Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., C.A. No. 1-18-
`
`cv-00758-LPS (D. Del.).
`
`Any questions concerning this paper may be directed to lead counsel.
`
`
`
`
`
`
`
`
`
`
`Dated: June 7, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4850-2264-5352.1
`
`Respectfully submitted,
`
`/Courtenay C. Brinckerhoff/
`Courtenay C. Brinckerhoff
`Registration No. 37,288
`
`Jason N. Mock
`Registration No. 69,186
`
`Counsel for Patent Owner
`Foley & Lardner LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`U.S. Patent No. 9,730,900
`IPR2018-00174
`
`CERTIFCATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Noven
`
`Pharmaceuticals, Inc.’s Updated Mandatory Notices Under 37 C.F.R. § 42.8
`
`was served on June 7, 2018, by email directed to the attorneys of record for the
`
`Petitioner at the following addresses:
`
`sparmelee@wsgr.com
`mrosato@wsgr.com
`jmills@wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`By: /Courtenay C. Brinckerhoff/
`Courtenay C. Brinckerhoff
`Registration No. 37,288
`
`Jason N. Mock
`Registration No. 69,186
`
`Counsel for Patent Owner
`Foley & Lardner LLP
`
`
`
`
`
`
`
`
`
`
`
`4850-2264-5352.1
`
`